Istari Oncology, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
- Conditions
- Solid TumorNon-muscle-invasive Bladder CancerBladder Cancer
- Interventions
- Biological: LerapolturevOther: 5% DDM
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Istari Oncology, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT04690699
- Locations
- 🇺🇸
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
EAP for the Treatment of Glioblastoma With PVSRIPO
- Conditions
- Glioblastoma
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Istari Oncology, Inc.
- Registration Number
- NCT04599647
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
- Conditions
- Melanoma
- Interventions
- Biological: LerapolturevBiological: Anti-PD-1 Checkpoint Inhibitor
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Istari Oncology, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT04577807
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients with Recurrent Glioblastoma
- Conditions
- Supratentorial GlioblastomaBrain TumorGlioblastomaRecurrent Glioblastoma
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Istari Oncology, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04479241
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
PVSRIPO for Patients With Unresectable Melanoma
- Conditions
- Melanoma
- Interventions
- Biological: PVSRIPO
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Istari Oncology, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03712358
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Examining Bioactivity of PVSRIPO in Invasive Breast Cancer
- Conditions
- Invasive Breast Cancer
- Interventions
- Biological: PVSRIPO
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Istari Oncology, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT03564782
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
- Conditions
- Malignant GliomaAnaplastic AstrocytomaGliosarcomaMedulloblastomaEpendymomaAnaplastic OligodendrogliomaPleomorphic Xanthoastrocytoma of BrainAnaplastic OligoastrocytomaGlioblastomaAtypical Teratoid/Rhabdoid Tumor of Brain
- Interventions
- Biological: Polio/Rhinovirus Recombinant (PVSRIPO)
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Istari Oncology, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03043391
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
PVSRIPO in Recurrent Malignant Glioma
- Conditions
- Malignant Glioma
- Interventions
- Biological: PVSRIPO
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Istari Oncology, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT02986178
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸UCSF Neurological Surgery, San Francisco, California, United States
PVSRIPO for Recurrent Glioblastoma (GBM)
- Conditions
- GBMGliomaGlioblastomaMalignant Glioma
- Interventions
- Biological: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Istari Oncology, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT01491893
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States